# Fine-tuning the yeast GAL10 promoter and growth conditions for efficient recombinant membrane protein production and purification

Rebecca Moussa, François Gellé, Sandrine Masscheleyn, Alexandre Pozza, Christel Le Bon, Karine Moncoq, Françoise Bonneté, Bruno Miroux

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Rebecca Moussa, François Gellé, Sandrine Masscheleyn, Alexandre Pozza, Christel Le Bon, et al. "Fine-tuning the yeast GAL10 promoter and growth conditions for efficient recombinant membrane protein production and purification." Protein Science, 2025, 34 (5), pp.e70125. 10.1002/pro.70125 hal-05200118

HAL Id: hal-05200118

https://cnrs.hal.science/hal-05200118v1

Submitted on 6 Aug 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
# Fine-tuning the Yeast GAL10 Promoter and Growth Conditions for Efficient Recombinant Membrane Protein Production and Purification.

Rebecca Moussa*, François Gellé, Sandrine Masscheleyn, Alexandre Pozza, Christel Le Bon, Karine Moncoq, Françoise Bonneté and Bruno Miroux*.

Université Paris Cité, CNRS, Biochimie des protéines membranaires, UMR7099, Paris, 75005, France

* Corresponding authors

Correspondences

Email: rebecca.moussa@ibpc.fr; bruno.miroux@ibpc.fr

KM, FB and BM are co-last authors

**Keywords:** Membrane protein production, *S. cerevisiae*, galactose promoter, solubilization, detergent.

**ABSTRACT:**

**Background:**

One of the most common issues in producing membrane proteins in heterologous expression systems is the low yield of purified protein. The solubilization efficiency of the recombinant membrane protein from biological membranes is often the limiting step.

**Results:** Here, we study the effects of titration of the GAL10-CYC promoter of *S. cerevisiae*, induction time, and culture media, on the rat mitochondrial uncoupling protein (UCP1) production and solubilization levels. We found that a maximum threshold of solubilized UCP1 (70%) is reached at 0.003% galactose concentration, independently of time, temperature, and detergent-to-protein ratio during solubilization. Supplementation with 0.1% amino acids of the S-lactate medium at induction resumes cell growth and recombinant production. The purified UCP1 protein (200 µg/L) is homogenous in DDM detergent and active after reconstitution in proteoliposomes. To extend the impact of our findings, we applied the same promoter titration to produce the GFP-AT7B human transporter and found an optimal galactose concentration of 0.0015%. The protein data bank analysis revealed that these galactose concentrations are 300 times lower than usual.

**Conclusions:** We propose a novel strategy for the recombinant production of membrane proteins in the yeast *S. cerevisiae*, which unlocks the use of this inexpensive eukaryotic host for membrane protein production.
## Introduction

The yeast expression system is widely used to produce endogenous or heterogenous eukaryotic proteins¹ ². S. cerevisiae host is well-characterized, cost-effective, easy to manipulate, and conserves basic cellular machinery and signal transducing pathways with higher eukaryotes. It is a preferred host system for the expression of eukaryotic proteins containing post-translational modifications (glycosylation, phosphorylation) that cannot be performed in bacterial expression systems. It also provides the possibility of functional *in vivo* or *in vitro* experiments on native organelles after their isolation. Yeast expression systems have been used for the structural determination of 180 membrane proteins, see³ and this study. The mammalian mitochondrial uncoupling protein 1 (UCP1) is an integral membrane protein found in the inner mitochondrial membranes of brown adipose tissue. It is responsible of non-shivering thermogenesis by its ability to burn off cellular nutrients as heat. UCP1 uncouples respiration from ATP synthesis by dissipating the electrochemical proton gradient⁴. It is a potential therapeutic target for treating obesity and diabetes by increasing energy expenditure. Functional and structural analyses of UCP1 have been achieved using S. cerevisiae as an expression host⁵,⁶. However, many questions about the mechanism of activation by free fatty acids are still unresolved. There is a need for a robust expression host able to support strong uncoupling of mitochondrial respiration induced by UCP1 variants that failed to be produced in HEK cells⁷. Heterologous protein expression in yeast is possible owing to the availability of a large set of promoters, selectable markers, and engineered strains³. However, solubilization of the recombinant protein from yeast membranes remains critical and often a limiting step ⁸,⁹ for further purification. GFP-based optimization scheme, selection of appropriate hosts, and growth temperature have been successfully applied to S. cerevisiae GAL1/10 promoter system for tuning membrane protein expression and purification¹⁰,¹¹. Here we propose a novel method of GAL1/10 promoter titration and culture medium optimization that resolves metabolic burden and toxicity associated with membrane protein overproduction, suppresses the formation of recombinant membrane protein aggregates, and significantly increases the efficiency of solubilization of the recombinant membrane protein from yeast membrane. We applied this approach to the purification and functional characterization of UCP1 and the effective solubilization of the human GFP-ATP7B transporter.

## Results

### Titration of UCP1 production in the yeast GAL10 promoter expression system

In this study, UCP1 is expressed using the pYeDP60 plasmid, where heterologous protein production is driven by the strong GAL10-CYC1 inducible fusion promoter, regulated by the Gal4 transcriptional activator. The W303.1b/Gal4 strain, which carries both the wild-type GAL4 gene and an integrated GAL10p-GAL4 cassette, ensures controlled Gal4 overproduction in response to galactose. In glucose-containing medium, GAL4 is repressed by constitutive inhibitor binding. Upon glucose depletion and galactose supplementation, GAL4 is released, activating the GAL10 promoter. This sequential induction leads to high GAL4 transactivator synthesis, followed by expression of the target protein from the plasmid (supplementary Figure 1).

Two protocols were designed mainly for practical purposes, as shown in Figure 1. The respiration protocol, with a media change, enables yeast spheroplast preparation on the same day for activity assays the following morning. This culture protocol for Respiration assay (R-culture) has been successfully applied to measure UCP1-dependent uncoupling of respiration on yeast spheroplasts⁶,¹².
The S-lactate medium is changed before induction at OD<sub>600nm</sub>=4, and galactose is added together with fresh medium and incubated for 4 h. The purification protocol allows cost-effective upscaling without additional media changes. In the culture protocol for UCP1 Purification (P-culture), UCP1 expression is induced by galactose addition at OD<sub>600nm</sub>=1 for 16 h without changing the media. To compare both protocols, yeast proteins are extracted and precipitated with TCA, and UCP1 levels are quantified by immunodetection. Figure 2A shows UCP1 and VDAC protein accumulation levels as a function of galactose concentration. Both protocols yield maximal amounts of UCP1 at 0.2% galactose and UCP1 protein levels start decreasing at 0.003% galactose. In the P-protocol, galactose concentration can be decreased to 0.025% without affecting the maximal levels of UCP1 production per cell. In the absence of the galactose inducer, UCP1 protein is not detected. Next, we investigated the time course of UCP1 production (Figure 2B). At 1% galactose concentration, UCP1 protein appears 30 minutes after the addition of galactose, whereas, at 0.2%, 0.05%, and 0.01% galactose concentration, UCP1 is first detected at 1 h, 2 h, and 4 h respectively. In all four conditions, UCP1 protein reached its maximum level of accumulation after 4 h without further increase after 16 h induction suggesting a limiting factor in the medium.

Effective solubilization of UCP1 is inversely correlated with galactose concentration

First, we tested three mild detergents and the n-Dodecyl phosphocholine (DPC) detergent, which was shown to inactivate UCP1 and other mitochondrial carriers¹², on crude mitochondrial fractions obtained from the P-protocol with 1% galactose Figure 3A. Mitochondrial membrane solubilization with n-Dodecyl-β-D-Maltopyranoside (DDM), Lauryl Maltose Neopentyl Glycol (LMNG), or 7-Cyclohexyl-1-Heptyl-β-D-Maltoside (Cymal-7) detergents at a detergent/protein ratio (w:w) of 10 results in poor extraction of UCP1 (around 3%, the upper 33 kDa band in the pellet fraction) but in full solubilization of VDAC, which appears as a lower 29 kDa band in the soluble fraction. In contrast, DPC partially solubilizes UCP1 (Figure 3A). This pattern of differential solubilization between DPC and other mild detergents suggests that the recombinant UCP1 is not correctly folded into the host membranes. We hypothesized that decreasing the UCP1 levels in yeast mitochondria may improve its extraction by mild detergents. At 0.05% galactose concentration, UCP1 solubilization is enhanced with DDM, LMNG, Cymal-7, and 1,2-dihexanoyl-*sn*-glycero-3-phosphocholine (DHPC) but not with 3-[(3-Cholamidopropyl)-Dimethylammonio]-1-Propane Sulfonate (CHAPS) and glyco-diosgenin (GDN) (Figure 3B). Adding cholesteryl hemisuccinate (CHS) to stabilize membrane proteins during solubilization¹⁰ does not improve solubilization levels except for DHPC. In contrast, at 0.003% galactose concentration the solubilization of UCP1 by DDM is strongly improved (Figure 3C, lane 60 min). A time course of UCP1 solubilization at 4°C with 10:1 DDM to protein ratio shows that the maximum level of UCP1 solubilization is reached in the first 15 minutes with no further improvement in the next 2 h incubation (Figure 3C). Increasing the temperature to 21°C does not increase the solubilization efficiency (data not shown). Decreasing the DDM to protein ratio to 1:1 at 10 mg/ml protein concentration shows similar results (Figure 3D) and is the most suitable for the next purification step.

Amino acids supplementation increases UCP1 production and yeast exponential phase length

Both R- and P-culture protocols yield similar amounts of UCP1 after 4 h and 16 h induction, respectively (Figure 2A). However, in both cases, the final OD<sub>600nm</sub> is below 5 suggesting a limiting
nutrient in the medium. In the R-culture protocol, not changing the medium indeed suppresses UCP1
production (Figure 4A). It has been shown that protein production in yeast under the ADH2 promoter
triggers a metabolic burden that adding a selected number of amino acids could partially resolve ¹³.
We hypothesized that supplementing the culture media with all amino acids during induction may
help restore cell growth and protein production. To test this hypothesis in the R-culture protocol,
amino acids (mix of 0.1% casamino-acids and 20 mg/l tryptophan) are added at induction time
(OD₆₀₀nm =4), and cells are collected 4 h later. Figure 4A shows that adding amino acids fully restores
UCP1 production regardless of galactose concentrations and slightly exceeds the effect of fresh
medium. Next, we investigated the optimal time and amounts of amino acids addition (Figure 4B).
Doubling amino acids concentration in S-lactate in the pre-induction culture at OD₆₀₀nm =0.03 had no
or limited effect on UCP1 production. Adding 5 times more amino acids at the time of induction does
not further increase UCP1 protein levels. Next, we tested the addition of amino acids in the P-culture
protocol. At galactose concentrations of 1 and 0.01%, the addition of amino acids does not affect
UCP1 expression. However, at the lowest concentration of galactose (0.003%, Figure 4C,
supplementary Figure 2A), amino acid addition increases 2.6 times UCP1 protein levels per cell (p ≤
0.001) as well as stimulates cell growth with a final OD₆₀₀nm =7.5 twice higher than without amino acids
(p ≤ 0.0001) (Figure 4D). The time course of UCP1 expression is not modified by addition of amino
acids; at 0.003% galactose, UCP1 is detected 4H after induction (Supplementary Figure 2B). Next, we
investigated the effect of galactose concentration and amino acids supplementation on cell growth
using a 48-well plate. Figure 4E shows that cell growth of UCP1-expressing yeasts is inversely
correlated with galactose concentration. At 1% galactose, yeast growth is strongly delayed and
decreased while at 0.003%, cell growth is restored and becomes identical to cells not expressing any
heterologous protein (empty vector 0%). Significant growth inhibition is seen at a high galactose
concentration (1%) on yeast cells harboring the empty vector. Amino acids supplementation increases
the exponential phase length, and consequently the final cell density.

In the R-optimized protocol with 0.003% galactose, the relative amount of UCP1 is 28% of VDAC
expression level (UCP1/VDAC = 0.277 +/- 0.017, Figure 5A), and the solubilization efficiency is below
10% with mild detergents and reaches 62% with DPC (Figure 5B). In contrast, at the same galactose
concentration, the P-optimized protocol yields a lower UCP1 expression level (UCP1/VDAC = 0.179 +/-
0.020, p ≤ 0.05) but higher biomass (Figures 5A and 4D), and enhanced solubilization ranging from
48% to 79% using DDM and Cymal-7, without further improvement by DPC (Figure 5B). As expected,
at 1% galactose, UCP1 expression increases significantly (UCP1/VDAC=1.182 +/- 0.246, p ≤ 0.05)
(Figure 5A); however, solubilization remains below 6% with mild detergents and reaches only 27%
with DPC (Figure 5B).

Large-scale purification of functional UCP1

Starting from 30 mg of yeast mitochondria solubilized with 1% DDM, 200 µg of UCP1 is purified as described in the Materials and Methods section. SDS-PAGE analysis shows a rather pure UCP1 sample (Figure 6A) after concentration at 1 mg/ml. Sample oligomeric state and mass of protein are assessed by SEC-MALLS (Figure 6B). In the first peak (blue curve) of the elution profile, corresponding to the UCP1-DDM-Cardiolipin (CL) complex, the experimental weight-averaged molar mass of UCP1 (43 kDa) is higher than the expected value for the monomeric form (32 kDa). This discrepancy might be due to a monomer-dimer equilibrium of UCP1 that could not be resolved with the size exclusion column used.
The second peak (the red curve) corresponds to the DDM-CL-free micelles. The experimental weight-average molar mass of the DDM-CL free micelles is around 93 kDa, a value superior to the expected weight-average molar mass of the DDM-free micelles, which is around 65 kDa ¹⁴. In this case, the mass difference is explained by the insertion of the CL in the DDM micelles.

As for UCP1 activity assessment, proton transport was measured upon its reconstitution in liposomes (Figure 6C and D) as previously described ¹⁵. UCP1 is well activated by 30 µM lauric acid (LA) and inhibited by 1 mM GDP until the basal activity level. The basal activity of proton transport is observed when no fatty acids are added, and it is completely inhibited by the addition of GDP. Control empty liposomes show that at the used concentration of LA to activate UCP1, they have no destabilizing effects on lipids (Figure 6D).

## Generalizing the yeast Gal10 optimized protocol for recombinant membrane protein purification

To extend the membrane protein coverage of our approach, we titrated the galactose promoter on yeast cells harboring the pYeDP60-GFP-ATP7B encoding a copper-transporting ATPase 2 ¹⁶ fused to a GFP-tag (generously given by Thibaud Dieudonné and Tomàs Heger). As initial screening, cells were grown on the 48-well plate with an adapted autoinduction protocol (see material and methods). A range of decreasing concentrations of galactose was added at the beginning of the culture in the presence of 0.1% glucose. Cell growth monitoring shows that 1% galactose impairs yeast cell growth (Figure 7A) as observed with UCP1. In the case of ATP7B, it is necessary to decrease galactose concentration up to 0.0015% to suppress the toxicity associated with the production of the GFP-ATP7B protein. GFP fluorescence monitoring shows a saturation curve of fluorescence intensity as a function of galactose concentrations in S-lactate in the presence or absence of amino acids. Since maximal fluorescence values are normalized by $OD_{600nm}$, the curve in Figure 7B reflects expression levels of ATP7B per cell. Amino acids supplementation slightly increases protein expression at low concentrations of galactose. At 0.003% galactose, the same expression levels are observed with or without amino acids supplementation. Above 0.003%, GFP fluorescence reaches its maximal level and the effect of amino acids addition is weaker. Of note cells with no addition of galactose exhibit a GFP fluorescence twice above the autofluorescence of yeast cells harboring the control empty vector.

Based on this analysis, galactose concentrations below 0.003% together with supplementation with amino acids were the culture conditions selected to avoid any negative side effects on cell growth and to test the solubilization efficiency of the recombinant transporter. Light and heavy membranes were prepared as described in the Materials and Methods section. Decreasing galactose concentration to 0.0015% does not affect GFP-ATP7B expression levels compared to 1% galactose, but it increases solubilization efficiencies of the recombinant protein from light membranes (from 7.8% to 33.5%) using Cymal-7-CHS detergent (Figure 7C and 7D). Induction with less than 0.0015% galactose is not beneficial as total protein levels start to decrease (Figure 7C). Moreover, while heavy membranes are completely insoluble when inducing with 1% galactose, 25 to 30% of solubilization is achieved using 0.0015% galactose (Figure 7D). DPC-CHS solubilization was effective no matter the galactose concentration (1% and 0.0015%), using both heavy and light membranes, which, as in the case of UCP1, suggests a misfolding of the recombinant protein when using high concentrations of galactose. Similarly to the production of UCP1, the P-protocol optimized by the addition of amino acids restores cell growth resulting in a final $OD_{600nm}$ of 9 (see Supplementary Table 7).

## PDB analysis of culture conditions used with *S. cerevisiae* as expression host.
To assess the novelty of our optimized protocol, we analyze the PDB as previously described ³ focusing on expression conditions with *S. cerevisiae* expression system. An up-to-date analysis of the PDB (Supplementary PDB file) shows 76 membrane protein structure entries obtained with the yeast *S. cerevisiae* as the expression host. The inducible GAL promoter is highly used (73,7%), with three different variants: GAL1 (63,2 %), GAL10/CYC1 (10,5 %, this study), and GAL10 (4%) (Table 1). The strength of the later promoter is weaker than that of GAL1¹⁷. The galactose concentrations added for induction of the expression of the recombinant protein range from 0.4% to 2% galactose with 2% being the most common. These concentrations are 100 to 1000 times higher than the optimized amounts used in this study. Induction periods range from 20 h to 72 h and for 12 occurrences, yeast cells were resuspended in a fresh medium at the time of induction (Figure 8A).

Discussion

Promoter engineering is a common approach to produce metabolites and proteins in microbial
systems. However, the design of expression systems is often motivated by maximizing the amount of
recombinant protein at the expense of the quality. In *E. coli* the T7 RNA polymerase-based expression
system is one of the most powerful systems to overproduce recombinant proteins. In the T7 BL21(DE3)
host, the addition of the IPTG inducer most of the times kill the cells and recombinant membrane
proteins have difficulties folding and inserting the *E. coli* membranes. Attenuated T7 hosts restore cell
growth, delay the time course of accumulation of the recombinant membrane protein, and favor its
folding and insertion¹⁸,¹⁹. Yeast expression systems are widely used for heterologous membrane
protein production, including from human origin.²⁰⁻²⁷ In the yeast *Saccharomyces cerevisiae* system,
increasing the strength of GAL promoters is achieved by controlling the sequence, number, and
substitution of upstream activating sequences of GAL promoter ²⁸. In our study, the GAL promoter
based expression system is enhanced by three means: (i), the pYeDP60 plasmid contains a promoter-
enhancing sequence of the cytochrome C oxidase gene is present immediately upstream of the GAL10
promoter, (ii), the modified W303.1b/Gal4 host strain contains a supplementary copy of the GAL4
transactivator protein (a, leu2, his3, trp1::TRP1-GAL10-GAL4, ura3, ade2-1, canr, cir+), (iii) at the time
of induction, the low amount of glucose (0.1%) initially present in the S-lactate and which attenuates
the GAL promoter activity, has been consumed. In the presence of glucose, GAL4 is indeed inactive.
When glucose is catabolized, the expression system is set up at its maximal capacity with 2% galactose
for induction, a culture temperature of 30°C, and 16-24 h of induction. This combination of induction
and culture conditions is the most widely used in structural biology of membrane protein (Figure 8A),
and contributed to 3% of unique membrane protein structures in the PDB³,²⁰. Among them, the yeast
expression system has succeeded in the biochemical and structural analyses of the human
mitochondrial carriers. Efficient heterologous expression in yeast has been observed for the human
citrate carrier²³, the dicarboxylate carrier and oxoglutarate carrier²²,²³, aspartate/glutamate
carrier²¹,²³, and the human uncoupling protein UCP1⁵, all induced with 0.4% galactose. In contrast, it
has also been reported that UCP1 and UCP3 are prone to aggregation and uncontrolled uncoupling of
respiration when expressed at high levels in the yeast *S. cerevisiae* and even at close to physiological
concentrations in the muscle L6 cell line⁸,²⁹,³⁰. Comparing galactose concentrations between studies is
difficult because yeast media and vector/host strain combinations are different¹³. For instance, we
use a variant of the W303.1b yeast strain harboring a supplementary copy of the Gal4 trans-activator,
which strongly enhances the activity of the promoter. We grow yeast in minimal lactate medium with
low (0.1%) glucose concentration and not in a rich YPG medium. Varying inducer concentration and
time of induction is a common practice during the optimization of membrane proteins production in
microbial systems. Nevertheless, here we show that downregulation of the promotor by ultra-low
concentration of inducer decreases the time course of expression of the recombinant membrane
protein, its final accumulation levels and ultimately, its solubilization efficiency. We used the natural
ability of the GAL10 promotor to be titrated with ultra-low (down to 0.009%) galactose concentrations
³²,³³. In the W303.1b/Gal4 strain and in lactate minimal medium, decreasing galactose to 0.025% does
not affect UCP1 or GFP-ATP7B protein levels. This is consistent with the results of Hovland *et al.* and
Ah Kang *et al.*, which have used galactose concentration down to 0.05% for the recombinant
production of human soluble proteins³³,³⁴. This first level of optimization not only decreases the cost
of large-scale fermentation of yeast but also avoids the side effects of high galactose concentrations
on the replicative lifespan of yeast cells and oxidative stress ³⁵. We indeed observed a negative effect
of 1% galactose on the growth of control yeast cells (Figure 4E). A second level of optimization is to
systematically compare the amount of inducer with the solubilization efficiency of the recombinant
membrane protein. For UCP1 and GFP-ATP7B, the optimal galactose concentrations are 0.003% and
0.0015% respectively, which are 1000 times less than the concentration we and other groups have
used for functional studies⁶,¹²,²¹⁻²³,²⁷,²⁶,²⁵,²⁴, and the most frequent galactose concentration observed
in the PDB-Membrane proteins (this study). This suggests that yeast processes correctly a limited
amount of recombinant membrane proteins and that the remaining excess of the overproduced
protein is misfolded or aggregated. The differential solubilization efficiency of Cymal-7 and DPC
detergents supports this analysis. DPC does not differentiate between folded and misfolded alpha-
helical membrane proteins³⁶. In the case of GFP-ATP7B, it readily solubilizes the recombinant protein
no matter the concentration of galactose while Cymal-7, solubilizes the membrane protein only at low
galactose concentrations (Figure 7D). A third level of optimization relates to nutrient conditions. At
0.003% galactose concentration, the time course of UCP1 production is delayed to a late stationary
phase where nutriments in S-lactate minimal medium become limiting. Here we show that
supplementation with amino acids at the induction time resumes the synthesis of the recombinant
proteins. It is as efficient as changing the culture medium, a usual practice, 12 out of 59 entries for the
GAL promotor system, found in the yeast PDB-MP (Figure 8A). A fourth parameter, not investigated in
this study, is the culture temperature. Decreasing the culture temperature at induction time in
microbial systems is a frequent practice³. In the yeast PDB-MP we found that 15 out of 59 entries had
an induction temperature below 30°C (Figure 8A). Interestingly, the expression protocols for AQP
proteins, Ca²⁺-ATPase, and lipid flippase complexes Drs2p/Cdc50p and ATP8B1/Cdc50p, which were
produced at the lowest temperatures in *S. cerevisiae* PDB-MP entries (15 and 18°C), employed strains
with the Gal4 enhancer (Figure 8B). The lower temperature may compensate for the overproduction
driven by the Gal4 enhancer, promoting the accumulation of correctly folded membrane
proteins²⁷,³⁷,³⁸. However, and in contrast of the fine-tuning of the galactose promotor, lowering culture
temperature has the drawback of decreasing cell machinery and biomass.

To conclude, the work presented here shows, in two independent examples, that titration of gal
promotor with an ultra-low concentration of galactose is a useful parameter to test for improving the
solubilization of some, not necessarily all, recombinant membrane proteins. Additionally, it reduces
toxicity associated with the expression of the target gene, and it is cost-effective for industrial large-
scale cultures.
# Material and methods

## Reagents

All reagents were purchased from Sigma-Aldrich unless specified in the text. All detergents were purchased from Anatrace except for DDM (Glycon).

## Yeast strain, expression vector

The GGATCCATGCATCACCATCACCATCACCATGAAAACTTGTACTTTCAATCAGGGTCGAC sequence was cloned between BamH1 and Sal1 of pYeD60 vector. It is coding for the MHHHHHHHHENLYFQSGST His8-TEV N-Terminal Tag peptide. The Rattus norvegicus UCP1 sequence (NCBI accession number NP-036814.1) was cloned between Sal1 and Kpn1 without codon optimization in frame with the N-Ter peptide. GFP-ATP7B is cloned in the pYeDP60 yeast expression vector as described in³⁹, a gift of Denis Pompon (TBI, Toulouse, France). Yeast *Saccharomyces cerevisiae* strain W303.1b/Gal4 (a, leu2, his3, trp1::TRP1-GAL10-GAL4, ura3, ade2-1, canr, cir+) (supplementary Figure 1) is transformed following the lithium acetate/ single-stranded carrier DNA polyethylene glycol method¹²,⁴⁰.

## UCP1 production in yeast

UCP1 expression is performed according to two different protocols (Figure 1). Respiration assay culture (R-culture) was previously validated by spheroplast respiration for the functional expression of UCP1 in yeast mitochondria ⁶,¹². Overnight yeast preculture is done at 30°C under 200 rpm agitation in S-lactate medium (2% lactate, 0.67% yeast nitrogen base without amino acids, 0.1% casamino acids (Fisher Scientific, Hampton, NH, USA), 9 mM ($NH_4)_2SO_4$, 7.3 mM $KH_2PO_4$, 98 µM tryptophan, pH 4.5) supplemented with glucose (0.1%). The starter culture is diluted at $OD_{600nm}$=0.03 in S-lactate medium with 0.1% glucose, and yeast cells are grown at 30°C under 200 rpm agitation. After 19 h of incubation, the yeast culture is at $OD_{600nm}$ =4. The medium is exchanged into a new S-lactate medium supplemented with different galactose concentrations for a 4 h induction at 30°C under 200 rpm agitation. On the other hand, the culture for protein purification (P-culture) was designed for large-scale cultures. To shorten the time of growth in S-lactate media, preculture is done overnight at 30°C under 200 rpm agitation in S-glucose medium (2% glucose, 0.67% yeast nitrogen base without amino acids, 0.1% casamino acids (Fisher Scientific, Hampton, NH, USA), 9 mM ($NH_4)_2SO_4$, 7.3 mM $KH_2PO_4$, 98 µM tryptophan, pH 5.5). The starter culture is diluted at $OD_{600nm}$ =0.3 in S-lactate medium supplemented with 0.1% glucose. After 6 h of incubation at 30°C, UCP1 expression is induced at $OD_{600nm}$=1, with the addition of galactose to the culture. UCP1 is produced for 16 h at 30°C under 200 rpm agitation.

## Preparation of yeast spheroplasts and isolation of mitochondria

Yeast cells are harvested by centrifugation (5 000 x g for 10 min), washed in water, and resuspended (10 ml/g of wet yeast pellet) in SED buffer (1M sorbitol, 25 mM EDTA, and 50 mM 1,4-dithiothreitol). After a 10 minutes incubation at 30°C, cells are washed with zymolyase buffer (sorbitol 1.2 M, $KH_2PO_4/K_2HPO_4$ 20 mM, pH 7.4), and resuspended (10 ml/g of yeast cells) in zymolyase buffer supplemented with 0.5 mg/ml Zymolyase-20T (Amsbio). Digestion of yeast cell walls is achieved during an incubation at 30 °C for 45 minutes. The resulting spheroplasts are washed three times (1 500 x g
centrifugation, 5 min) with respiration buffer (1 M sorbitol, 0.5 mM EDTA, 2 mM MgSO₄, 1.7 mM NaCl, 10 mM KH₂PO₄/K₂HPO₄, 0.1% Bovine Serum Albumin fatty acids free, pH 6.8).

The final washed pellet is resuspended in respiration buffer and cell lysis is performed using the Yeda Press (Nitrogen cavitation). The cell suspension is collected into a pre-cooled cavitation chamber. Under stirring at 4°C, it is subjected to 500 psi for 10 minutes. At the end of this step, the pressure in the chamber falls to approximately 350 psi for another 10 minutes. The cell suspension is then released through outflow tubing attached to the bottom valve and the depressurization of the cell suspension from 350 psi to normal atmospheric pressure led to a highly efficient cell breakage ⁴¹. The integrity of mitochondria issued from this method is preserved as studied by respiration assays (Data not shown). To get rid of unbroken and partially disrupted cells, cell homogenate is centrifuged at 1000 x g at 4°C for 10 minutes. The resulting supernatant is centrifuged at 12600 x g for 30 minutes to sediment mitochondria. The obtained crude mitochondrial fraction is resuspended in a freezing buffer (10% Trehalose, 100 mM Tris-HCl pH 7.5), and stored at -70°C after flash-freezing with liquid nitrogen. Proteins in the mitochondrial fraction are quantified by BCA method with BSA as the standard.

## Extraction of total yeast proteins

Volumes of cultures (ml) corresponding to a constant OD₆₀₀nm of 5 (V = 5 / OD₆₀₀nm) are centrifuged at 5000 x g for 10 minutes. Harvested cells were resuspended with 400 µl of cold 5% TCA. Upon the addition of glass beads, yeast cells are broken using a vortex for 5 minutes at maximum speed. The supernatant is collected and beads are washed two times with 500 µL cold 2% TCA. All supernatants are pooled and chilled on ice for 15 minutes. Proteins are pelleted by centrifugation at 16000 x g for 15 minutes at 4°C. Pellets are resuspended with 100 µL of 100 mM Tris-HCl pH 8 and 8 M urea.

## Immunodetection of UCP1

The same amount of total protein extracts (1 µg) or mitochondrial proteins (10 µg) among all expression protocols and all biological replicates are loaded on a 12% SDS-PAGE gel and transferred onto a nitrocellulose membrane (GE Healthcare). UCP1 is revealed using a mouse anti-penta-Histidine HRP-conjugate 0.2 µl/ml (Bio-Rad, catalogue number: MCA5995P, clone: ABD 2.2.20). VDAC1 Porin is used as a mitochondrial loading control and detected by a mouse anti-VDAC1 0.1 µl/ml (Invitrogen, catalogue number: 459500, clone: 16G9E6BC4) and an HRP-coupled goat anti-mouse antibody 0.1 µl/ml (Promega, catalogue number: W4021, polyclonal). Peroxidase activity is detected using the Pierce ECL Western Blot Kit (Thermo Fisher Scientific), and intensities of the bands are calculated using Image Lab software (6.1; Bio-Rad, Hercules, CA, USA). The relative amount of UCP1 protein is quantified using the UCP1/VDAC band intensity ratio. Uncropped scans of all blots are provided as a Source Data file.

## Solubilization assays

Mitochondria are thawed and buffer is exchanged for solubilization buffer (150 mM NaCl, 50 mM HEPES, 20 mM imidazole) to a final concentration of 1 mg/ml for a detergent to protein ratio = 10 or 10 mg/ml for the detergent to protein ratio = 1, as the final concentration of detergent is 10 mg/ml (1%). Crude mitochondria are solubilized at 4°C for one hour. Ultracentrifugation at 100000 x g for 1 h separates the insoluble proteins (pellet) from the soluble ones (supernatant).
Pellets are resuspended in the same initial volume before centrifugation in 20% SDS and 8 M urea. The same volume of Total, Supernatant, and Pellet fractions are loaded on SDS-PAGE.

## Purification of UCP1

The Ni-NTA resin (Thermo Fisher Scientific) is pre-washed with buffer A (300 mM NaCl, 50 mM HEPES, 20 mM imidazole, 0.03% DDM, 0.1 mg/ml Cardiolipin (Avanti Polar Lipids)). The solubilized mitochondrial fraction is supplemented with 150 mM NaCl before batch binding to 1 ml of Ni-NTA resin for one hour at 4°C. The resin is washed under gravity flow with 20 ml of buffer A, followed by 20 ml of buffer B (150 mM NaCl, 50 mM HEPES, 20 mM imidazole, 0.03% DDM, 0.03 mg/ml Cardiolipin). Proteins are eluted from the Ni-NTA resins with elution buffer (150 mM NaCl, 50 mM HEPES, 300 mM imidazole, 0.03% DDM, 0.03 mg/ml Cardiolipin), supplemented with 50 units of histidine-tagged TEV protease. Elution fractions are pooled and dialyzed (membrane cut-off = 10Kda) in dialysis buffer: (150 mM NaCl, 50 mM HEPES, 0.03% DDM, 0.5 mM TCEP, and 0.1 mM EDTA) at 4°C. The resulting TEV-cleaved UCP1 protein is loaded onto a second 500 µL Ni-NTA Resin equilibrated with dialysis buffer. After incubation at 4°C for 1 h, the flow-through containing the TEV-cleaved UCP1 is collected and concentrated. The final UCP1 concentration was determined by spectrophotometry according to the Beer-Lambert law.

## Reconstitution in liposomes and proton flux assay

For liposomes preparation, 5 mg of phosphatidylethanolamine (PE) (Egg PE sigma P7943, DPPE Avanti 850705), 5 mg of Cardiolipin and 40 mg of phosphatidylcholine (PC) (Avanti 840051) are solubilized in 5 ml of internal buffer (70 mM K₂SO₄, 5 mM KH2PO4 pH 6.8). The suspension is homogenized by vortexing and subjected to ultrasounds on ice for 2 x 5 minutes at 70 Watts using Bioblock Scientific VibraCell 72446.

Purified UCP1, 40 µg, is incorporated into liposomes at 4°C for 1 h in the presence of 0.3% Triton X-100. Detergent elimination is achieved by two incubations with 150 mg Bio-Beads (Bio-Rad) for 1h30, followed by a third incubation with 200 mg Bio-Beads for 2 h.

UCP1 proton transport assay in liposomes is adapted from Mozo et al ⁴². Safranine probe aggregates as function of membrane potential (ΔΨ). Upon the addition of nigericin that exchanges H⁺ against K⁺ (H⁺ in, K⁺ out), a ΔpH is created. By letting protons out of liposome; UCP1 converts the ΔpH gradient into ΔΨ. The safranin absorbance at 520 nm is inversely proportional to ΔΨ thus it decreases due to UCP1 protonophoric activity. A control with empty liposomes ensures that the used concentration of fatty acids (30 µM of lauric acid) does not have any destabilizing effect on the lipidic membrane. When indicated, 1 mM of GDP is added to inhibit UCP1 activity. At the end of the experiment, a chemical uncoupler (CCCP) is added to let all protons going out to the external side of liposome and to calculate ΔΨmax, a value that is proportional to the internal volume of liposomes. Slopes of safranine curves are normalized by ΔΨmax.

## SEC-MALLS analysis of the purified UCP1

Quality control of the purified UCP1 sample was checked by size exclusion chromatography (SEC) coupled to a multiple-angle laser light scattering (MALLS). This experiment was carried out at room
temperature on a Shimadzu HPLC coupled to three detectors, 1) a UV-VIS detector SPD-20A (Shimadzu) for absorbance measurements at 280 nm, 2) an Optilab T-rEX refractometer (Wyatt Technology), for the differential refractive index (dRI) measurements at 658 nm and 3) a miniDawn TREOS detector (Wyatt Technology) for static light scattering intensity measurements at three different angles (44, 90, and 136°), at 658 nm. A 24-ml Superdex 200 Increase column (10/300, Cytiva) was used to separate protein-detergent complex and protein-free detergent micelles. The system was equilibrated overnight with a mobile phase containing 50 mM HEPES pH 7, 150 mM NaCl, 0.03% DDM, and 0.03 g/ml Cardiolipin at a flow rate of 0.3 ml/min. Once the UV, LS, and RI signals are stable, the buffer baseline is subtracted for each detector. Inter-detector delay and peak-broadening corrections are done using a sample of bovine serum albumin (i.e., 25 µl of BSA at 5 mg/ml dissolved in the mobile phase) as a monodisperse standard protein of known molar mass (66 kDa). Purified UCP1 (100 µl at 1 mg/ml) was then injected through the column. The absolute molar mass of UCP1-DDM-Cardiolipin complexes and protein-free micelles were obtained without column calibration, by using the module "Protein Conjugate" from the software Astra (Wyatt Technology). The molar mass of the complex is calculated from the following Rayleigh equation:

$$ \Delta R(\theta) = K \cdot M_{wcomplex} \cdot [complex] \left(\frac{\partial n}{\partial c}\right)_{complex}^2 $$

Where K, Mw, (∂n/∂c)_{complex} are, respectively, an optical constant, the weight-average molecular mass of the complex, and the refractive index increment of the complex.

Knowing the respective extinction coefficients and refractive index increments of both the protein and the detergent micelles, we can obtain the molar mass fraction of UCP1 and protein-bound detergent. The methodology of mass calculation is thoroughly described in 43.

For UCP1, ε<sup>0.1%</sup> at 280 equals 0.783 (mg/ml)<sup>-1</sup>.cm<sup>-1</sup> and ∂n/∂c = 0.187 ml.g<sup>-1</sup> calculated from sequence using SedFit software (sedfitsedphat.nibib.nih.gov), and for the DDM:CL micelles, ε<sup>0.1%</sup> = 0 and ∂n/∂c = 0.146 ml.g<sup>-1</sup> measured by injecting increasing concentrations of DDM:CL mixtures directly in the refractometer.

## Yeast cell growth and fluorescence monitoring

Yeast cell growth expressing UCP1 or ATP7B was studied by Optical Density measurements at 600 nm using the CLARIOstar Plus Microplate Reader which was also put into service for GFP of ATP7B fluorescence measurements, and the SPECTROstar Nano. Both machines are from BMG LABTECH (GmbH, Germany). After an overnight preculture of yeast cells in S-lactate media supplemented with 0.01% glucose at 30°C at 200 rpm, the culture was diluted to OD<sub>600 nm</sub>=0.1 in new S-lactate media with 0.1% glucose, and the appropriate galactose concentrations in a 48-well plate. The plate is then incubated in the machine to assess OD<sub>600 nm</sub> and/ or fluorescence (30 min/ cycle) at 30°C with agitation before each reading. It is important to note that the auto-induction and oxygenation conditions in this experiment differ from those applied to the protocols of Figure 1. S-lactate media absorbance intensities were subtracted from raw data. Yeast cells with empty pYeDP60 vector were taken as a
negative control with no stress due to protein expression. For the fluorescence measurements, values
were normalized by OD<sub>600 nm</sub> at each time point.

ATP7B: Cell lysis, and membrane preparation

For the copper transporter ATP7B experiments, cell culture was carried out according to the purification protocol. Harvested cells were directly subjected to lysis with Cell-D disruptor, with no spheroplast preparation step beforehand. To ensure high efficiency of lysis, cells that were resuspended in 50 mM Tris-HCl pH 7, 20 mM EDTA, and 100 mM sucrose, were broken during three repeated cycles with maximal pressure (40 000 PSI). Unbroken cells and cell debris were sedimented and removed at 1500 x g for 10 minutes, then centrifugation at 20 000 x g for 30 minutes allowed obtaining heavy membranes in the pellet. The corresponding supernatant was finally subjected to a 120 000 x g ultracentrifugation for one hour, and light membrane fraction was therefore sedimented. The next steps were performed similarly to UCP1 protocols with the following exceptions: 1) MgCl₂ was added onto the solubilization buffer, and both Cymal-7 and DPC were mixed with CHS according to a 1:4 detergent to CHS ratio, 2) for the separation of soluble and insoluble parts after solubilization, the ultracentrifugation was done at 120 000 x g. Samples were run to SDS-PAGE gels (10% acrylamide) and fluorescence of GFP was monitored by typhoon biomolecular imager (GE Healthcare).

PDB analysis

Structural studies of membrane proteins need large quantities of homogeneous and correctly folded
proteins. By focusing on PDB data, we can identify and analyze systems that optimize the production
of the required quantity and quality of these challenging proteins. Therefore, the protein structures
registered in "mpstruc membrane protein of known 3D structure", Dr. Stephen White's database at
UC Irvine (https://blanco.biomol.uci.edu/mpstruc/), were used as a basis to analyze expression and
solubilization conditions, with data available up to the end of 2023. An entry corresponds to the
structure of a membrane protein that has been published in a peer-reviewed journal and is therefore
identified by its PDB number. There is a distinction between the terms "unique protein" and
"published report". The date of the "unique protein" structure marks the anteriority; other similar
protein structures (same organism of origin) filled and published later will be considered as "published
reports". As the same protein can be expressed, solubilized, purified and characterized under different
conditions, working on the set of unique proteins and published reports will enable us to work on a
larger panel.

After having manually curated database entries (excluding structures without membrane protein
domains), among the 3353 entries (for unique and published membrane proteins), 15.1% were
obtained from native proteins, 38.3% were expressed in *E. coli*, 38.5% in eukaryotic systems, 5.4% in
yeast, and 4.8% in other systems. Our study focused on the expression of membrane proteins in yeast,
and more specifically in *S. cerevisiae*. Of the 180 entries for yeast (5.4%), 76 correspond to *S. cerevisiae*
(42.2%), 59 to *K. Pastoris* (32.8%), 41 to *P. Pastoris* (22.8%) and 4 to *S. Pombe* (2.2%). For this set of 76
membrane proteins expressed in *S. cerevisiae*, extracted variables from mpstruc database, Uniprot
(https://www.uniprot.org/) and from the Protein Data Bank in Europe (https://www.ebi.ac.uk/pdbe/)
were: PDB, Type, UniprotKB code, protein or complex name and molecular weight. Additional
variables on expression parameters (strain, plasmid, promotor, induction time, induction
temperature, inductor concentration, medium) and solubilization parameters (detergent) were then
consistently retrieved by reading the literature. All the variables that were analyzed are presented in the supplementary PDB file.

## Statistical analyses and replicates

Statistical analyses with multiple unpaired t-tests were done on PRISM software: Supplementary Tables 1, 2 for Figure 4, Supplementary Table 3, 4 for Figure 5, Supplementary Table 5 for Figure 6D, Supplementary Table 6 for Figure 7, and Supplementary Table 7. The number of replicates is provided in the Figure legend. Bars indicate means +/- SEM in Figures 4D, 5, and 7D. For Figure 6D, boxes of the box plots indicate the first quartile, the median, and the third quartile. The whisker length is 1.5 times the interquartile range.. Replicates for Figures 4D, 5A, 5B, and 7D are shown in Supplementary Figures 2, 3, 4, and 5, respectively. In the figures, the following correspondences may be found: ns = not significant; *, *p* ≤ 0.05; **, *p* ≤ 0.01; ***, *p* ≤ 0.001 and ****, *p* ≤ 0.0001; *p* ≤ 0.05 was considered as statistically significant.
<table><caption>**Table 1:** Promoter distribution among the 76 entries of supplementary PDB File.</caption><thead><tr><th>Promoter</th><th>Promotor Family</th><th>Occurrences</th><th>%</th></tr></thead><tbody><tr><td><strong>ADH2</strong></td><td></td><td></td><td></td></tr><tr><td>ADH2</td><td>Other promoters</td><td>2</td><td>2.6</td></tr><tr><td><strong>Galactose</strong></td><td></td><td></td><td></td></tr><tr><td>GAL1</td><td>Galactose promoters</td><td>48</td><td>63.2</td></tr><tr><td>GAL10/CYC1</td><td>Galactose promoters</td><td>8</td><td>10.5</td></tr><tr><td>GAL10</td><td>Galactose promoters</td><td>3</td><td>4</td></tr><tr><td><strong>Constitutive</strong></td><td></td><td></td><td></td></tr><tr><td>PMA1 (constitutive)</td><td>Constitutive promoters</td><td>12</td><td>15.8</td></tr><tr><td>PDR5 (constitutive)</td><td>Constitutive promoters</td><td>1</td><td>1.3</td></tr><tr><td>GAP (constitutive)</td><td>Constitutive promoters</td><td>1</td><td>1.3</td></tr><tr><td><strong>Native</strong></td><td></td><td></td><td></td></tr><tr><td>Native</td><td>Native promoters</td><td>1</td><td>1.3</td></tr><tr><td><strong>Total</strong></td><td>-</td><td><strong>76</strong></td><td><strong>100</strong></td></tr></tbody></table>
Figures

**Figure 1:** Culture protocols for UCP1 expression in yeast S. cerevisiae. In both protocols, yeast cells are cultured in S-lactate minimal medium to maintain respiratory metabolism while maintaining selective pressure and preventing plasmid loss to ensure tighter regulation of expression. Respiration protocol culture (R-culture): UCP1 is induced at OD<sub>600nm</sub> = 4 in fresh medium for 4 h. Large-scale culture for purification (P-culture): induction is done at OD<sub>600nm</sub> = 1 for 16 h.

<figure><img src="image_3.png" /></figure>
**Figure 2:** Kinetics of UCP1 production in yeast depend on galactose concentrations. Cultures volumes (mL) corresponding to a constant OD600nm = 5 (V = 5/OD600nm) are harvested and proteins are precipitated by TCA. Equivalent amounts of total protein extracts (1 µg) are loaded in each well for valid comparison. UCP1 (33 kDa band) and mitochondrial porin VDAC (29 kDa) are immunodetected. (a) Effect of the galactose concentration (indicated in %) on UCP1 levels in R- and P-cultures. (b) Time-course of UCP1 accumulation in yeast. UCP1 inclusion bodies produced in E. coli (50 and 500 ng) are loaded as positive controls in panels (a) and (b), respectively.

<figure><img src="image_4.png" /></figure>
**Figure 3:** Solubilization of UCP1 from crude mitochondria is inversely correlated to galactose concentrations. UCP1 is induced at OD600nm = 1 for 16 h using the P-protocol with (a) 1%, (b) 0.05%, (c, d) 0.003% galactose. In (b), the presence of CHS in DDM micelles (1:4 ratio) is tested (/_/+). Solubilization is held at 4_C for 1 h (a, b) or monitored over time (c, d). Detergent concentration is 1% and protein concentrations are 1 mg/mL except for (d) at 10 mg/mL. CM = crude mitochondria. Soluble (S) and pellet (P) fractions are separated by ultracentrifugation at 100,000g and equivalent volumes are analyzed by Western blot. UCP1 levels are estimated by immunodetection as described in section 4. In panel (a) both UCP1 (33 kDa band) and mitochondrial porin VDAC (29 kDa band) are immunodetected. UCP1 inclusion bodies produced in E. coli (50 ng) are loaded as positive controls in panels (a), (c), and (d).

<figure><img src="image_5.png" /></figure>

<figure><img src="image_6.png" /></figure>

<figure><img src="image_7.png" /></figure>

<figure><img src="image_8.png" /></figure>
**Figure 4:** Amino acid supplementation at induction stimulates yeast growth and UCP1 production. (a) Yeast cells are induced at OD600nm = 4 with a range of galactose concentrations from 0.003 to 1% in (a) fresh S-lactate media (R-culture), (b) the same medium, and (c) the same medium with amino acid supplementation (0.1%) at induction. (b) Optimization of amino acid supplementation on UCP1 levels using protocol (Figure 4a) (c). Amino acids (0.2%) are added at inoculation (OD600nm = 0.03) (a) or at induction (OD600nm = 1) at 0.1% (b) or 0.5% (c). (c) Application of amino acid supplementation to P-culture. UCP1 is induced using 0.003, 0.01, and 1% galactose ± 0.1% amino acids at induction (OD600nm = 1). (d) Characterization of the P-optimized protocol. UCP1 is induced with 0.003% galactose without (blue) or with (green) 0.1% amino acids. Left panel shows UCP1/VDAC intensities ratios on TCA extracts (see Figure S2). Right panel shows the final OD600nm of cell cultures. Experiments were conducted with n = 5; bars indicate means ± SEM. Statistical analyses with multiple unpaired t-tests were done on PRISM (see Tables S1 and S2). (e) Effects of amino acids supplementation and galactose on yeast cell growth. Representative growth curves were monitored with a CLARIOstar Plus Microplate Reader. Cells from preculture are diluted to OD600nm = 0.1 in S lactate media supplemented with 0.1% glucose and 1% (red), 0.003% galactose (brown and dark blue). Control cells harboring an empty pYeDP60 vector are shown in gray (0% galactose) and pink (1% galactose). The optimized P-culture (0.003% galactose, 0.1% amino acids) is in dark blue. Data are representative of two to three independent experiments.

<figure><img src="image_9.png" /></figure>
**Figure 5.** Quantification of UCP1 levels and solubilization efficiencies in large-scale cultures. Culture conditions are: P-optimized culture (P-opti in purple) _ induction with 0.003% galactose at OD600nm = 1 with 0.1% amino acids for 16 h; Control P-culture (P-control in blue) _ induction with 1% galactose at OD600nm = 1 for 16 h; R-AA culture (R-AA in green) _ induction with 0.003% galactose at OD600nm = 4 and with 0.1% amino acids for 4 h in the same medium. (a) Expression levels of UCP1 in crude mitochondria: the relative amount UCP1/VDAC (intensity band ratio) is indicated (see Figure S3). (b) Solubilization efficiencies: detergents were used at 1% with protein concentration of 10 mg/mL (P opti and R-AA) or 1 mg/mL (P-control) (see Figure S4). Experiments were conducted with n = 3 and bars indicate means ± SEM. Statistical analyses with unpaired t-tests were done on PRISM (Tables S3 and S4).

<figure><img src="image_10.png" /></figure>
**Figure 6.** Purification, biophysical characterization, and functional analysis of UCP1 from P-optimized protocol. (a) Two-step purification of UCP1 in DDM on Ni-NTA affinity chromatography. The 16% SDS PAGE gel shows, respectively, crude mitochondria (CM), DDM-solubilized fraction (S), first Ni-NTA elution (N1 elution), cleaved UCP1 by TEV protease overnight (OVN TEV), flow-through of the second Ni-NTA (N2 FT), concentrated UCP1, and agarose beads of the second Ni-NTA (N2 bound). (b) SEC-MALLS analysis of UCP1 in DDM-Cardiolipin micelles (blue) and protein-free micelles (red). Samples are eluted using a Superdex 200 Increase (10/300) column. Molar masses are calculated and depicted for UCP1-DDM-CL complex (■), UCP1 protein (+), and its bound detergent-CL complex (x). (c) Representative UCP1 protonophoric activity. Kinetics curves of the safranine polarization were monitored at 520 nm. The arrows indicate the addition of nigericin and CCCP. Ligands were added before nigericin: 30 µM lauric acid (black), or 30 µM lauric acid with 1 mM GDP (pink). The green curve corresponds to basal activity. See Table S5 for statistical analysis of UCP1 activity and regulation. (d) UCP1 protonophoric activity in liposomes in response to 30 µM lauric acid (LA) or 1 mM GDP or both (blue). Empty liposomes serve as a negative control (purple). Slopes were normalized to liposome volume (estimated from CCCP values). Nigericin is added at the start of each measurement. Sample sizes: for UCP1 liposomes-nigericin (n = 6), GDP (n = 5), LA (n = 8), LA and GDP (n = 8); for empty liposomes-nigericin (n = 8), GDP (n = 2), LA (n = 6), LA and GDP (n = 9). Boxplots represent the first quartile, median, and third quartile. The whisker length is 1.5 times the interquartile range. Statistical analyses with unpaired t-tests were done on PRISM (Table S5).

<figure><img src="image_11.png" /></figure>
**Figure 7** Application of P-optimized protocol to GFP-ATP7B transporter. (a) Growth curves of cells expressing GFP-ATP7B in S-lactate media monitored using a CLARIOstar Plus Microplate Reader (as described in Figure 4e). GFP-ATP7B was induced by different galactose concentrations: 1% (black and red), 0.01% (gray), 0.0015% (green), and 0% (purple). Amino acids are supplemented in all cases except for the one represented by the red curve. The experiment was repeated twice with similar results. (b) Green fluorescence intensities per cell of GFP-ATP7B as a function of galactose concentration. Maximum fluorescence is recorded after 35 h of culture. The effect of amino acids supplementation is shown (red: without, blue: with). The x-axis is represented by a log scale where 0.0001% galactose corresponds to 0%. The dotted line represents control cells harboring the empty pYeDP60 vector, with amino acid addition. The experiment was repeated twice with similar results. (c) Comparison of ATP7B solubilization efficiencies from light (top) and heavy membranes (bottom) using Cymal-7 supplemented with CHS. GFP-ATP7B is produced following P-culture conditions with either 1% galactose or a range of galactose concentrations (0.0015–0%) with amino acids supplementation. Membranes (Mb) correspond to the starting material while S corresponds to the solubilized fraction. GFP fluorescence intensities on 10% SDS-PAGE gels are assessed by a typhoon laser scanner (GE Healthcare). (d) Quantification of GFP-ATP7B solubilization efficiency from light (light color) or heavy membranes (dark color). GFP-ATP7B was induced according to the P-optimized conditions (except for galactose concentration with 0.0015% instead of 0.003%, green) or the P-control conditions (1% galactose, blue). Solubilization is performed with 1% Cymal-7-CHS or DPC-CHS for 1 mg/mL of proteins. Experiments were conducted with n = 4, and bars indicate means ± SEM (see Figure S5 and Table S6).

<figure><img src="image_12.png" /></figure>
**Figure 8:** Comprehensive description of culture conditions and S. cerevisiae strains from the PDB-MP database. (a) Schematic representation of induction period as a function of galactose concentration and temperature of culture. The symbol size is proportional to the number of occurrences. Fresh medium used before induction is indicated by a circle, while unchanged medium is indicated by a square. This set of complete data consists of 40 entries from Data S2. (b) Induction temperature usage by strain. The size of the symbol is relative to the number of occurrences. The complete data set (strain, induction temperature) consists of 44 entries. Strains with the Gal4 enhancer are indicated in bold.

<figure><img src="image_13.png" /></figure>
## Author's contributions

RM and BM designed the study and performed and analyzed all the experiments. CL and KM constructed and analyzed the yeast PDB-MP. FG and SM, performed and analyzed UCP1 activity assay and growth condition optimization of GFP-ATP7B. AP and FB performed and analyzed the Sec-Malls experiments. RB and BM wrote the paper with contributions from all authors. KM, FB, and BM are co-last authors.

## Acknowledgments

The authors acknowledge support from: Centre National de la Recherche Scientifique (MITI interdisciplinary program "Modélisation du Vivant" 2021 & 2022 and Tremplin@INP 2021), Institut National de la Santé et de la Recherche Médicale (BM), Université Paris Cité (KM), Agence nationale de la Recherche (LABEX DYNAMO (ANR-11-LABX 0011), Equipex CACSICE (ANR-11-EQPX-0008), Institut de convergence Qlife for PhD program to RM (ANR-17-CONV-0005)), and Ecole Normale Supérieure PhD program to FG. We thank Thibaud Dieudonné and Tomàs Heger for the pYeDP60-GFP-AT7B yeast expression plasmid gift.

## Conflict of Interest

None of the authors have a conflict of interest to disclose

## References

(1) Phan, L.; Schoenfeld, L. W.; Valášek, L.; Nielsen, K. H.; Hinnebusch, A. G. A Subcomplex of Three eIF3 Subunits Binds eIF1 and eIF5 and Stimulates Ribosome Binding of mRNA and tRNAiMet. *EMBO J.* **2001**, *20* (11), 2954–2965. https://doi.org/10.1093/emboj/20.11.2954.

(2) Ton, V.-K.; Rao, R. Functional Expression of Heterologous Proteins in Yeast: Insights into Ca2+ Signaling and Ca2+-Transporting ATPases. *Am. J. Physiol.-Cell Physiol.* **2004**, *287* (3), C580–C589. https://doi.org/10.1152/ajpcell.00135.2004.

(3) Dilworth, M. V.; Piel, M. S.; Bettaney, K. E.; Ma, P.; Luo, J.; Sharples, D.; Poyner, D. R.; Gross, S. R.; Moncoq, K.; J F Henderson, P.; Miroux, B.; Bill, R. M. Microbial Expression Systems for Membrane Proteins. *Methods San Diego Calif* **2018**, *147*, 3–39. https://doi.org/10.1016/j.ymeth.2018.04.009.

(4) Nicholls, D. G. Mitochondrial Proton Leaks and Uncoupling Proteins. *Biochim. Biophys. Acta BBA - Bioenerg.* **2021**, *1862* (7), 148428. https://doi.org/10.1016/j.bbabio.2021.148428.

(5) Jones, S. A.; Gogoi, P.; Ruprecht, J. J.; King, M. S.; Lee, Y.; Zögg, T.; Pardon, E.; Chand, D.; Steimle, S.; Copeman, D. M.; Cotrim, C. A.; Steyaert, J.; Crichton, P. G.; Moiseenkova-Bell, V.; Kunji, E. R. S. Structural Basis of Purine Nucleotide Inhibition of Human Uncoupling Protein 1. *Sci. Adv.* **2023**, *9* (22), eadh4251. https://doi.org/10.1126/sciadv.adh4251.

(6) Gagelin, A.; Largeau, C.; Masscheleyn, S.; Piel, M. S.; Calderón-Mora, D.; Bouillaud, F.; Hénin, J.; Miroux, B. Molecular Determinants of Inhibition of UCP1-Mediated Respiratory Uncoupling. *Nat. Commun.* **2023**, *14* (1), 2594. https://doi.org/10.1038/s41467-023-38219-9.
(7) Kang, Y.; Chen, L. Structural Basis for the Binding of DNP and Purine Nucleotides onto UCP1. *Nature* **2023**, *620* (7972), 226–231. https://doi.org/10.1038/s41586-023-06332-w.

(8) Stuart, J. A.; Harper, J. A.; Brindle, K. M.; Jekabsons, M. B.; Brand, M. D. A Mitochondrial Uncoupling Artifact Can Be Caused by Expression of Uncoupling Protein 1 in Yeast. *Biochem. J.* **2001**, *356* (Pt 3), 779–789. https://doi.org/10.1042/0264-6021:3560779.

(9) Winkler, E.; Heidkaemper, D.; Klingenberg, M.; Liu, Q.; Caskey, T. UCP3 Expressed in Yeast Is Primarily Localized in Extramitochondrial Particles. *Biochem. Biophys. Res. Commun.* **2001**, *282* (1), 334–340. https://doi.org/10.1006/bbrc.2001.4563.

(10) Dieudonné, T.; Jaxel, C.; Lejeune, M.; Lenoir, G.; Montigny, C. Expression in Saccharomyces Cerevisiae and Purification of a Human Phospholipid Flippase. *Methods Mol. Biol. Clifton NJ 2023*, *2652*, 231–246. https://doi.org/10.1007/978-1-0716-3147-8_13.

(11) Drew, D.; Newstead, S.; Sonoda, Y.; Kim, H.; von Heijne, G.; Iwata, S. GFP-Based Optimization Scheme for the Overexpression and Purification of Eukaryotic Membrane Proteins in Saccharomyces Cerevisiae. *Nat. Protoc.* **2008**, *3* (5), 784–798. https://doi.org/10.1038/nprot.2008.44.

(12) Piel, M. S.; Masscheleyn, S.; Bouillaud, F.; Moncoq, K.; Miroux, B. Structural Models of Mitochondrial Uncoupling Proteins Obtained in DPC Micelles Are Not Functionally Relevant. *FEBS J.* **2021**, *288* (9), 3024–3033. https://doi.org/10.1111/febs.15629.

(13) Görgens, J. F.; van Zyl, W. H.; Knoetze, J. H.; Hahn-Hägerdal, B. Amino Acid Supplementation Improves Heterologous Protein Production by Saccharomyces Cerevisiae in Defined Medium. *Appl. Microbiol. Biotechnol.* **2005**, *67* (5), 684–691. https://doi.org/10.1007/s00253-004-1803-3.

(14) Barret, L.-A.; Barrot-Ivolot, C.; Raynal, S.; Jungas, C.; Polidori, A.; Bonneté, F. Influence of Hydrophobic Micelle Structure on Crystallization of the Photosynthetic RC-LH1-PufX Complex from Rhodobacter Blasticus. *J. Phys. Chem. B* **2013**, *117* (29), 8770–8781. https://doi.org/10.1021/jp403483q.

(15) Zoonens, M.; Comer, J.; Masscheleyn, S.; Pebay-Peyroula, E.; Chipot, C.; Miroux, B.; Dehez, F. Dangerous Liaisons between Detergents and Membrane Proteins. The Case of Mitochondrial Uncoupling Protein 2. *J. Am. Chem. Soc.* **2013**, *135* (40), 15174–15182. https://doi.org/10.1021/ja407424v.

(16) Bitter, R. M.; Oh, S.; Deng, Z.; Rahman, S.; Hite, R. K.; Yuan, P. Structure of the Wilson Disease Copper Transporter ATP7B. *Sci. Adv.* **2022**, *8* (9), eabl5508. https://doi.org/10.1126/sciadv.abl5508.

(17) Da Silva, N. A.; Bailey, J. E. Influence of Plasmid Origin and Promoter Strength in Fermentations of Recombinant Yeast. *Biotechnol. Bioeng.* **1991**, *37* (4), 318–324. https://doi.org/10.1002/bit.260370405.

(18) Schlegel, S.; Löfblom, J.; Lee, C.; Hjelm, A.; Klepsch, M.; Strous, M.; Drew, D.; Slotboom, D. J.; de Gier, J.-W. Optimizing Membrane Protein Overexpression in the Escherichia Coli Strain Lemo21(DE3). *J. Mol. Biol.* **2012**, *423* (4), 648–659. https://doi.org/10.1016/j.jmb.2012.07.019.

(19) Angius, F.; Ilioaia, O.; Amrani, A.; Suisse, A.; Rosset, L.; Legrand, A.; Abou-Hamdan, A.; Uzan, M.; Zito, F.; Miroux, B. A Novel Regulation Mechanism of the T7 RNA Polymerase Based Expression
System Improves Overproduction and Folding of Membrane Proteins. *Sci. Rep.* **2018**, *8* (1), 8572.
https://doi.org/10.1038/s41598-018-26668-y.

(20) Carlesso, A.; Delgado, R.; Ruiz Isant, O.; Uwangue, O.; Valli, D.; Bill, R. M.; Hedfalk, K. Yeast as a Tool for Membrane Protein Production and Structure Determination. *FEMS Yeast Res.* **2022**, *22* (1), foac047. https://doi.org/10.1093/femsyr/foac047.

(21) Tavoulari, S.; Lacabanne, D.; Pereira, G. C.; Thangaratnarajah, C.; King, M. S.; He, J.; Chowdhury, S. R.; Tilokani, L.; Palmer, S. M.; Prudent, J.; Walker, J. E.; Kunji, E. R. S. Distinct Roles for the Domains of the Mitochondrial Aspartate/Glutamate Carrier Citrin in Organellar Localization and Substrate Transport. *Mol. Metab.* **2024**, *90*, 102047. https://doi.org/10.1016/j.molmet.2024.102047.

(22) Pyrihová, E.; King, M. S.; King, A. C.; Toleco, M. R.; van der Giezen, M.; Kunji, E. R. S. A Mitochondrial Carrier Transports Glycolytic Intermediates to Link Cytosolic and Mitochondrial Glycolysis in the Human Gut Parasite Blastocystis. *eLife* **2024**, *13*, RP94187.
https://doi.org/10.7554/eLife.94187.

(23) Cimadamore-Werthein, C.; King, M. S.; Lacabanne, D.; Pyrihová, E.; Jaiquel Baron, S.; Kunji, E. R. Human Mitochondrial Carriers of the SLC25 Family Function as Monomers Exchanging Substrates with a Ping-Pong Kinetic Mechanism. *EMBO J.* **2024**, *43* (16), 3450–3465.
https://doi.org/10.1038/s44318-024-00150-0.

(24) Kintzer, A. F.; Stroud, R. M. Structure, Inhibition and Regulation of Two-Pore Channel TPC1 from Arabidopsis Thaliana. *Nature* **2016**, *531* (7593), 258–262.
https://doi.org/10.1038/nature17194.

(25) Fiorini, L.; Mus-Veteau, I. Method to Screen Multidrug Transport Inhibitors Using Yeast Overexpressing a Human MDR Transporter. *Methods Mol. Biol. Clifton NJ* **2016**, *1432*, 303–318.
https://doi.org/10.1007/978-1-4939-3637-3_19.

(26) Moncoq, K.; Kemp, G.; Li, X.; Fliegel, L.; Young, H. S. Dimeric Structure of Human Na+/H+ Exchanger Isoform 1 Overproduced in Saccharomyces Cerevisiae. *J. Biol. Chem.* **2008**, *283* (7), 4145–4154. https://doi.org/10.1074/jbc.M704844200.

(27) Lenoir, G.; Menguy, T.; Corre, F.; Montigny, C.; Pedersen, P. A.; Thinès, D.; le Maire, M.; Falson, P. Overproduction in Yeast and Rapid and Efficient Purification of the Rabbit SERCA1a Ca2+–ATPase. *Biochim. Biophys. Acta BBA - Biomembr.* **2002**, *1560* (1), 67–83.
https://doi.org/10.1016/S0005-2736(01)00458-8.

(28) Deng, J.; Wu, Y.; Zheng, Z.; Chen, N.; Luo, X.; Tang, H.; Keasling, J. D. A Synthetic Promoter System for Well-Controlled Protein Expression with Different Carbon Sources in Saccharomyces Cerevisiae. *Microb. Cell Factories* **2021**, *20* (1), 202. https://doi.org/10.1186/s12934-021-01691-3.

(29) Echtay, K. S.; Winkler, E.; Bienengraeber, M.; Klingenberg, M. Site-Directed Mutagenesis Identifies Residues in Uncoupling Protein (UCP1) Involved in Three Different Functions. *Biochemistry* **2000**, *39* (12), 3311–3317. https://doi.org/10.1021/bi992448m.

(30) Harper, J. A.; Stuart, J. A.; Jekabsons, M. B.; Roussel, D.; Brindle, K. M.; Dickinson, K.; Jones, R. B.; Brand, M. D. Artifactual Uncoupling by Uncoupling Protein 3 in Yeast Mitochondria at the Concentrations Found in Mouse and Rat Skeletal-Muscle Mitochondria. *Biochem. J.* **2002**, *361* (Pt 1),
49–56. https://doi.org/10.1042/0264-6021:3610049.

(31) Peng, B.; Williams, T. C.; Henry, M.; Nielsen, L. K.; Vickers, C. E. Controlling Heterologous Gene Expression in Yeast Cell Factories on Different Carbon Substrates and across the Diauxic Shift: A Comparison of Yeast Promoter Activities. *Microb. Cell Factories* **2015**, *14*, 91.
https://doi.org/10.1186/s12934-015-0278-5.

(32) Lee, M. E.; DeLoache, W. C.; Cervantes, B.; Dueber, J. E. A Highly Characterized Yeast Toolkit for Modular, Multipart Assembly. *ACS Synth. Biol.* **2015**, *4* (9), 975–986.
https://doi.org/10.1021/sb500366v.

(33) Ah Kang, H.; Kyu Kang, W.; Go, S.-M.; Rezaee, A.; Hari Krishna, S.; Ki Rhee, S.; Kim, J.-Y. Characteristics of Saccharomyces Cerevisiae gal1Δ and gal1Δhxk2Δ Mutants Expressing Recombinant Proteins from the GAL Promoter. *Biotechnol. Bioeng.* **2005**, *89* (6), 619–629.
https://doi.org/10.1002/bit.20240.

(34) Hovland, P.; Flick, J.; Johnston, M.; Sclafani, R. A. Galactose as a Gratuitous Inducer of GAL Gene Expression in Yeasts Growing on Glucose. *Gene* **1989**, *83* (1), 57–64.
https://doi.org/10.1016/0378-1119(89)90403-4.

(35) Liu, P.; Young, T. Z.; Acar, M. Yeast Replicator: A High-Throughput Multiplexed Microfluidics Platform for Automated Measurements of Single-Cell Aging. *Cell Rep.* **2015**, *13* (3), 634–644.
https://doi.org/10.1016/j.celrep.2015.09.012.

(36) Chipot, C.; Dehez, F.; Schnell, J. R.; Zitzmann, N.; Pebay-Peyroula, E.; Catoire, L. J.; Miroux, B.; Kunji, E. R. S.; Veglia, G.; Cross, T. A.; Schanda, P. Perturbations of Native Membrane Protein Structure in Alkyl Phosphocholine Detergents: A Critical Assessment of NMR and Biophysical Studies. *Chem. Rev.* **2018**, *118* (7), 3559–3607. https://doi.org/10.1021/acs.chemrev.7b00570.

(37) Bjørkskov, F. B.; Krabbe, S. L.; Nurup, C. N.; Missel, J. W.; Spulber, M.; Bomholt, J.; Molbaek, K.; Helix-Nielsen, C.; Gotfryd, K.; Gourdon, P.; Pedersen, P. A. Purification and Functional Comparison of Nine Human Aquaporins Produced in Saccharomyces Cerevisiae for the Purpose of Biophysical Characterization. *Sci. Rep.* **2017**, *7* (1), 16899. https://doi.org/10.1038/s41598-017-17095-6.

(38) Azouaoui, H.; Montigny, C.; Ash, M.-R.; Fijalkowski, F.; Jacquot, A.; Grønberg, C.; López-Marqués, R. L.; Palmgren, M. G.; Garrigos, M.; le Maire, M.; Decottignies, P.; Gourdon, P.; Nissen, P.; Champeil, P.; Lenoir, G. A High-Yield Co-Expression System for the Purification of an Intact Drs2p-Cdc50p Lipid Flippase Complex, Critically Dependent on and Stabilized by Phosphatidylinositol-4-Phosphate. *PloS One* **2014**, *9* (11), e112176. https://doi.org/10.1371/journal.pone.0112176.

(39) Urban, P.; Werck-Reichhart, D.; Teutsch, H. G.; Durst, F.; Regnier, S.; Kazmaier, M.; Pompon, D. Characterization of Recombinant Plant Cinnamate 4-Hydroxylase Produced in Yeast. Kinetic and Spectral Properties of the Major Plant P450 of the Phenylpropanoid Pathway. *Eur. J. Biochem.* **1994**, *222* (3), 843–850. https://doi.org/10.1111/j.1432-1033.1994.tb18931.x.

(40) Daniel Gietz, R.; Woods, R. A. Transformation of Yeast by Lithium Acetate/Single-Stranded Carrier DNA/Polyethylene Glycol Method. In *Methods in Enzymology*; Guthrie, C., Fink, G. R., Eds.; Guide to Yeast Genetics and Molecular and Cell Biology - Part B; Academic Press, 2002; Vol. 350, pp 87–96. https://doi.org/10.1016/S0076-6879(02)50957-5.
(41) Wang, Y.; Lilley, K. S.; Oliver, S. G. A Protocol for the Subcellular Fractionation of Saccharomyces Cerevisiae Using Nitrogen Cavitation and Density Gradient Centrifugation. *Yeast Chichester Engl. 2014*, **31** (4), 127–135. https://doi.org/10.1002/yea.3002.

(42) Mozo, J.; Ferry, G.; Masscheleyn, S.; Miroux, B.; Boutin, J. A.; Bouillaud, F. Assessment of a High-Throughput Screening Methodology for the Measurement of Purified UCP1 Uncoupling Activity. *Anal. Biochem. 2006*, **351** (2), 201–206. https://doi.org/10.1016/j.ab.2006.01.033.

(43) Gimpl, K.; Klement, J.; Keller, S. Characterising Protein/Detergent Complexes by Triple-Detection Size-Exclusion Chromatography. *Biol. Proced. Online 2016*, **18**, 4. https://doi.org/10.1186/s12575-015-0031-9.